Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of DSP-5423P in Patients with Schizophrenia (Phase 3)
jRCT2080222713Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of blonanserin in schizophrenia, sponsored by Sumitomo Pharma. Primary endpoints: Long-term safety of DSP-5423P and Long-term effectiveness of DSP-5423P. Started Jan 2015; status: completed.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080222713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222713.